The European Society for Medical Oncology (ESMO) is the leading professional organisation for medical oncology. With more than 25,000 members representing oncology professionals from over 160 countries worldwide, ESMO is the society of reference for oncology education and information. ESMO is committed to offer the best care to people with cancer, through fostering integrated cancer care, supporting oncologists in their professional development, and advocating for sustainable cancer care worldwide.
The Association of European Cancer Leagues (ECL) is a non-profit, pan-European umbrella organisation of 30 national and regional cancer societies. ECL provides an exclusive platform for members and partners to collaborate with their international peers, primarily in the areas of cancer prevention, tobacco control, access to medicines and patient support, and creates opportunities to advocate for these issues at the EU level.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Cancer 52 is an alliance of organisations in the United Kingdom working to address the inequalities that exist in policy, services and research into the less common cancers and to improve outcomes for patients with these highly challenging diseases.
The mission of the Chordoma Foundation is to rapidly develop effective treatments and ultimately a cure for chordoma, while improving the diagnosis, treatment, and quality of life for people affected by this devastating bone cancer.
The CML Advocates Network is a worldwide network of non-profit organisations supporting patients with Chronic Myeloid Leukemia (CML) and their relatives.
The European Cancer Patient Coalition (ECPC) represents the views of cancer patients in the European healthcare debate and provides a forum for European cancer patients to exchange information and share best practice experiences. With more than 450 members from all EU Member States and beyond, ECPC is the European largest cancer patient association representing patients with all types of cancer from the most common to the rarest.
The intent of the European Head & Neck Society (EHNS) is to promote exchange of knowledge in all aspects of head and neck neoplastic diseases and to promote the highest standards of research, education and training, disease prevention and patient care.
The European Hematology Association promotes excellence in patient care, research, and education in hematology. It serves medical professionals, researchers, and scientists with an active interest in hematology. It is the largest European-based organization connecting hematologists worldwide to support career development and research, harmonize hematology education, and advocate for hematologists and hematology.
The aim of the European Institute of Oncology (IEO) is to implement an innovative model for health and advanced research in the international oncology field, from basic laboratory research that tries to grapple with the genetic roots of cancer – through to advanced clinical research such as testing new drugs, with the unifying goal which is to treat patients more effectively.
The European LAM Patient Federation focuses on supporting lymphangioleiomyomatosis (LAM) research and coordinating communication with existing LAM patient groups. The Federation brings and collaborates with research teams working internationally.
The European Oncology Nursing Society is a pan-European organization dedicated to the support and development of cancer nurses. Through our individual members and national societies we engage in projects to help nurses develop their skills, network with each other and raise the profile of cancer nursing across Europe.
The European Organisation for Rare Diseases (EURORDIS) is an alliance of patient organisations and individuals active in the field of rare diseases, dedicated to improving the quality of life of all people living with rare diseases in Europe.
The aims of the European Organisation for Research and Treatment of Cancer (EORTC) are to develop, conduct, coordinate, and stimulate translational and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patient quality of life.
EURACAN is the European Reference Networks for rare, low prevalence and complex diseases on adult cancer (solid tumour). It is a virtual network involving 66 healthcare providers across 17 countries in Europe.
The European School of Oncology (ESO) is committed to improving the skills of all health professionals dealing with cancer patients and to shortening the length of time needed to transfer knowledge from research centres to daily practice, combining advanced technology with humanism in care.
The European Society for Paediatric Oncology (SIOP Europe, or SIOPE) is the single, united European organisation of academia and healthcare professionals dedicated to childhood and teenage cancer and is working in close partnership with patient, parent and survivor groups across Europe.
The aims of the European Society of Pathology (ESP) are to advance pathology in Europe and to facilitate communication between European pathologists.
The European Society for Radiotherapy and Oncology (ESTRO) is an international scientific society fostering the role of Radiation Oncology in the treatment of cancer, supporting all the radiation oncology professionals and the wider oncology community in their daily practice. ESTRO’s vision statement for 2030 ‘”Radiation Oncology. Optimal Health for All, Together” emphasizes the ambition of the Society to further reinforce radiation oncology as core partner in multidisciplinary cancer care and to guarantee accessible and high-value radiotherapy for all cancer patients who need it. ESTRO is actively focused on translating science and evidence into practice, supporting continuous professional development and embracing its role in policy, through a broadening network of partnerships with all relevant stakeholders.
The European Society of Surgical Oncology (ESSO) aims to ensure that the highest possible standard of surgical treatment is available to all cancer patients throughout Europe. To this end, ESSO facilitates the dissemination of knowledge and expertise within the surgical oncology community through a range of activities including education, research and leadership in multidisciplinary care.
The European, Middle Eastern, & African Society for Biopreservation and Biobanking (ESBB) is an international not-for-profit organization under Belgium law, located in Brussels, Belgium. ESBB’s mission is to advance biosharing for a better world through mobilizing, inspiring, and educating the biobank community across EMEA.
ESBB represents all aspects of biobanking and biopreservation of biological resources, including biobank management, data quality assurance and pre-analytics, automation, IT solutions, research and innovation, education, ethical, legal, regulatory and social issues. Our members represent the full spectrum of individuals, academic institutions, including leading university hospitals and clinical trial consortiums, and companies with valuable expertise in the aforementioned domains. It is a biobanking and biosharing focused society that is international, interdisciplinary and inter-sectoral.
Built from the merging of two European networks of excellence dedicated to clinical research in bone (EuroBoNet) and Connective Tissue (ConTiCaNET) sarcomas, euroSARC gathers worldclass European expertise in the field of sarcomas. The project aims at developing a specific and rigorous research framework and methodology to pursue these clinical trials testing specific strategies for rare sarcoma subtypes.
The objectives of the Fondazione IRCCS Istituto Nazionale dei Tumori include research into cancer, to better understand the biological mechanisms and to improve the systems of diagnosis and treatment; diagnosis and treatment of cancer, with the methods that are recognized internationally as the most valid; and cancer information for citizens and training of medical and nursing staff involved in the treatment of cancer.
GIST Cancer UK is a charitable trust committed to the promotion and protection of the physical and mental health of patients with Gastro-Intestinal Stromal Tumours (GIST) in the United Kingdom.
The Grupo Español de Tumores Huérfanos e Infrecuentes (GETHI) (Spanish Group for Research on Orphan and Uncommon Tumors) is a Cooperative Group of medical professionals that was established by the Spanish Society for Medical Oncology (SEOM) to better address the issues surrounding rare and uncommon cancers.
The International Brain Tumour Alliance (IBTA) seeks to be an alliance of the support, advocacy and information groups for brain tumour patients and carers in different countries and also includes researchers, scientists, clinicians and allied health professionals who work in the area of brain tumours.
The International Kidney Cancer Coalition (IKCC) is an independent and democratic network of patient support and advocacy organizations established with the mission of improving the quality of life of patients and their families living with kidney cancer. IKCC provides information, support and assistance to national kidney cancer organizations.
Eli Lilly and Company (Lilly) is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded in 1876 by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission.
The Melanoma Patient Network Europe (MPNE) is a European Patient Network that educates and advocates for research and access in Melanoma.
Myeloma Patients Europe (MPE) is an umbrella organisation of myeloma patient groups and associations from across Europe, acting as a network of highly efficient, effective and sustainable myeloma and AL amyloidosis patient organisations with the mission of providing education, information and support across the MPE member network and to advocate at European, national and local levels for the best possible research and equal access to the best possible treatment and care.
The National Medical Research Radiology Center of the Ministry of Healthcare of the Russian Federation is a federally controlled medical centre focused on three branches of research: radiology, urology and oncology. Read more about the Center.
Novartis' purpose is to reimagine medicine to improve and extend people's lives. We use innovative science and technology to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
Orphanet is a multi-lingual database dedicated to information on rare diseases.
Pfizer's purpose is to deliver breakthroughs that change patients’ lives. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.
Rare Cancers Society, Russian Federation and CIS countries, is an organization focusing on the challenge of rare tumours in the territory of the Russian Federation and CIS countries. Their priorities are to develop educational programmes for oncologists and to establish reference centres, biobanks of tissues and blood samples, and a database of patients with rare cancers.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
The Sarcoma Patients EuroNet Association (SPAEN) works to extend information services, patient support and advocacy to patient organisations for the benefit of sarcoma patients across the whole of Europe.
The Università degli Studi di Milano (University of Milan) is a public teaching and research university. It is a leading institute in Italy and Europe for scientific productivity.
The World Sarcoma Network (WSN) is a global network of national sarcoma trials groups and research organisations with the mission to stimulate rapid clinical drug development for sarcomas and enable performance of clinical studies that a cooperative group could not complete on its own.
Would your organisation like to become a partner? Please contact us.